ASH 2018: Gilead präsentiert Forschungsergebnisse zu hämatoilogischen Malignomen und soliden Tumoren

Gilead wird zu Onkologie und Zelltherapie auf dem 60th Meeting der American Society of Hematology (ASH) in San Diego 12 abstracts präsentieren, darunter Ergebnisse zu der ZUMA CAR-T-Zelltherapie. So gibt es Langzeitdaten für Yescarta® (Axicabtagene ciloleucel) der ZUMA-1-Studie und aktuelle Daten der ZUMA-3-Studie mit KTE-X19 bei erwachsenen Patienten mit rezidivierter oder refraktärer ALL.

Abstracts:

Cell Therapy Presentations, Large B-Cell Lymphoma
Abstract #2967 (Poster)
Sunday, Dec 2 (6:00-8:00 pm)
2-Year Follow-Up and High-Risk Subset Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients With Refractory Large B Cell Lymphoma Solid Tumors

Abstract #492 (Oral)
Sunday, Dec 2 (5:45 pm)
Regression of Epithelial Cancers Following T Cell Receptor Gene Therapy Targeting Human Papillomavirus-16 E7 Large B-Cell Lymphoma

Abstract #678 (Oral)
Monday, Dec 3 (11:45 am)
Analysis of CAR-T and Immune Cells within the Tumor Micro-Environment of Diffuse Large B-Cell Lymphoma Post CAR-T Treatment By Multiplex Immunofluorescence Large B-Cell Lymphoma

Abstract #697 (Oral)
Monday, Dec 3 (10:30 am)
Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR ALL

Abstract #897 (Oral)
Monday, Dec 3 (5:00 pm)
Updated Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Large B-Cell Lymphoma

Abstract #4192 (Poster)
Monday, Dec 3 (6:00-8:00 pm)
End of Phase 1 Results From ZUMA-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination With Atezolizumab for the Treatment of Patients With Refractory Diffuse Large B Cell Lymphoma Large B-Cell Lymphoma

Abstract #4779 (Poster)
Monday, Dec 3 (6:00-8:00 pm)
Cost-Effectiveness of Axicabtagene Ciloleucel for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Italy

Abstract #4795 (Poster)
Monday, Dec 3 (6:00-8:00 pm)
Comparing Survival for Different CAR Ts: Need for Addressing Bias Due to Differences in the Pre-Infusion Period
Additional Key Hematology Presentations CLL/FL

Abstract #2302 (Poster)
Saturday, Dec 1 (6:15-8:15 pm)
Real-World Clinical Management of Patients Treated with Idelalisib in France: A Study of 529 Cases of Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphoma (FL) CLL

Abstract #3135 (Poster)
Sunday, Dec 2 (6:00-8:00 pm)
Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia CLL/FL

Abstract #3149 (Poster)
Sunday, Dec 2 (6:00-8:00 pm)
Survival Outcomes Following Idelalisib Interruption in the Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia CLL

Abstract #4428 (Poster)
Monday, Dec 3 (6:00-8:00 pm) Results From a Prospective Real World Study Show Strong Efficacy of Idelalisib in CLL, Including High-Risk CLL, and Provide Evidence That PJP Prophylaxis Positively Impacts On Overall Survival

Quelle: Gilead